

Jain P, Bhardwaj YR, Kishore D. Simultaneous determination of amlodipine and olmesartan in human plasma by liquid chromatography tandem mass spectrometry and its application in pharmacokinetic study. *Bull. Pharm. Res.* 2016;6(2):36-44.

References (22):

1. Basaveswara Rao MV, Nagendrakumar AVD, Sivanadh M, Venkata Rao G. Validated RP-HPLC method for the estimation of telmisartan in tablet formulation. *Bull. Pharm. Res.* 2012;2(2):50-5.
<https://www.appconnect.in/app/journalUploads/dp-5-1.pdf>
2. Bhimavarapu R, Chitra KP, Meda H, Kanikanti D, Anne M, Gowthami N. Forced degradation study of paracetamol in tablet formulation using RP-HPLC. *Bull. Pharm. Res.* 2011;1(3):13-7.
<https://www.appconnect.in/wp-content/uploads/2012/06/ReprintBPR027.pdf>
3. Bramlage P, Wolf WP, Stuhr T, Fronk EM, Erdlenbruch W, Ketelhut R, Schmieder RE. Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. *Vasc. Health Risk Manag.* 2010;6:803-11.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2941791/pdf/vhrm-6-803.pdf>
4. Chen SH, Wu CF, Chen BM, Pei Q, Tan HY, Yang L, Yang GP. High-performance liquid chromatography-mass spectrometry for determining olmesartan in human plasma. *Nan Fang Yi Ke Da Xue Xue Bao* 2008;28(6):1104-5.
<https://www.ncbi.nlm.nih.gov/pubmed/18583274>
5. Chhabra GS, Banerjee SK. Stability indicating assay method development and validation of dronedarone hydrochloride in its bulk form by RP-HPLC. *Bull. Pharm. Res.* 2013;3(2): 58-65.
<http://journal.appconnect.in/wp-content/uploads/2013/08/ReprintBPR073.pdf>
6. Haria M, Wagstaff AJ. Amlodipine: A Reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. *Drugs* 1995;50(3):560-86.
<https://www.ncbi.nlm.nih.gov/pubmed/8521773>
7. Liu D, Hu P, Matsushima N, Li X, Li L, Jiang J. Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci.* 2007;856(1-2):190-7.
<https://www.ncbi.nlm.nih.gov/pubmed/17602900>
8. Liu D, Jiang J, Wang P, Feng S, Hu P. Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci.* 2010; 878(9-10):743-8.
<https://www.ncbi.nlm.nih.gov/pubmed/20153270>

9. Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. *J. Cardiovasc. Pharmacol.* 2005; 46(5): 585-93.
<https://www.ncbi.nlm.nih.gov/pubmed/16220064>
10. Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, Koike H. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. *Eur. J. Pharmacol.* 1995; 285(2):181-8.
<https://www.ncbi.nlm.nih.gov/pubmed/8566137>
11. Murdoch D, Heel RC. Amlodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. *Drugs* 1991;41(3): 478-505.
<https://www.ncbi.nlm.nih.gov/pubmed/1711448>
12. Patwari A, Dabhi M, Rathod I, Desai U, Suhagia BN, Sharma M. Simultaneous determination of ofloxacin and cefixime in combined tablet dosage form by HPLC and absorbance correction method. *Bull. Pharm. Res.* 2014;4(3):112-7.
<http://journal.appconnect.in/wp-content/uploads/2015/01/Reprintbpr100.pdf>
13. Punzi H, Neutel JM, Kereiakes DJ, Shojaee A, Wawerczak WF, Dubiel R, Maa JF. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR trial evaluating blood pressure reductions and control (AZTEC) study. *Ther. Adv. Cardiovasc. Dis.* 2010;4(4):209-21.
<https://www.ncbi.nlm.nih.gov/pubmed/20519261>
14. Qi W, Zhao Q, Jiang J, Hu P. Simultaneous determination of olmesartan and amlodipine in human plasma and urine by ultra performance liquid chromatography tandem mass spectrometry. *J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci.* 2013;938:27-34.
<https://www.ncbi.nlm.nih.gov/pubmed/24036499>
15. Sengupta P, Sarkar AK, Bhaumik U, Chatterjee B, Roy B, Chakraborty US, Pal TK. Development and validation of an LC-ESI-MS/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application. *Biomed. Chromatogr.* 2010;24(12):1342-9.
<https://www.ncbi.nlm.nih.gov/pubmed/21077253>
16. Shah S, Asnani A, Kawade D, Dangre S, Arora S, Yende S. Quantitative analysis of olmesartan medoxomil and amlodipine besylate in plasma by high-performance liquid chromatography technique. *J. Young Pharm.* 2012;4(2):88-94.
<https://www.ncbi.nlm.nih.gov/pubmed/22754260>
17. Shrestha DM, Srinivasa Rao T, Sreedhar C, Akkamma HG, Bharadwaja Reddy G, Yadav PK. Development and validation of new analytical method for the simultaneous estimation of naproxen and esomeprazole in bulk and pharmaceutical formulation. *Bull. Pharm. Res.* 2016; 6(1):28-35.
<http://journal.appconnect.in/wp-content/uploads/2015/05/ReprintBPR1271.pdf>

18. Singh S, Dahiya R. Stability-indicating RP-HPLC method for estimation of atorvastatin calcium in solid dosage form. *Bull. Pharm. Res.* 2014;4(1):9-13.
<http://journal.appconnect.in/wp-content/uploads/2014/05/ReprintBPR086.pdf>
19. Yanagisawa H, Amemiya Y, Knazaki T, Shimoji Y, Fujimoto K, Kitahara Y, Sada T, Mizuno M, Ikeda M, Miyamoto S, Furukawa Y, Koike H. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure–activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. *J. Med. Chem.* 1996;39(1):323-38.
<https://www.ncbi.nlm.nih.gov/pubmed/8568823>
20. Zhou Y, Li J, He X, Jia M, Liu M, Li H, Xiong Z, Fan Y, Li W. Development and validation of a liquid chromatography-tandem mass spectrometry method for simultaneous determination of amlodipine, atorvastatin and its metabolites ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human plasma and its application in a bioequivalence study. *J. Pharm. Biomed. Anal.* 2013;83:101-7.
<https://www.ncbi.nlm.nih.gov/pubmed/23711572>
21. US FDA, Guidance for industry: Bioanalytical Method Validation. US Food and Drug Administration, Rockville, MD, 2001.
<http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf>
22. Yu Y, Hou YN, HU YQ, Wang J, Liu JF, Zhao W. Pharmacokinetics of olmesartan, a new angiotensin II receptor blocker, in Chinese healthy subjects. *Asian J. Pharmacodyn. Pharmacokinet.* 2006;6(2):219-23.
<https://www.hitpages.com/doc/5749247517392896/1#pageTop>